Assembly Biosciences Inc. is a clinical-stage biotechnology company focused on developing novel antiviral therapeutics for serious viral diseases worldwide. Its pipeline features long-acting helicase-primase inhibitors ABI-5366 and ABI-1179, currently in Phase 1a/1b clinical studies targeting recurrent genital herpes caused by herpes simplex virus. The company is also advancing ABI-4334, a next-generation capsid assembly modulator in Phase 1b trials designed to disrupt the hepatitis B virus replication cycle, and ABI-6250, an oral hepatitis delta virus entry inhibitor in Phase 1a studies. Additional candidates include ABI-7272, a broad-spectrum non-nucleoside polymerase inhibitor for transplant-related herpesviruses. Assembly Biosciences Inc. leverages expertise in virology to create innovative oral therapies aimed at improving treatment outcomes for patients with chronic viral infections like hepatitis B and delta, as well as herpesviruses. Founded in 2005 and headquartered in South San Francisco, California, the company plays a key role in the biotechnology sector by addressing unmet needs in antiviral drug development.